Core Viewpoint - The company, Tuoxin Pharmaceutical (301089.SZ), announced that its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd., has received two "Drug GMP Compliance Inspection Notification Letters" from the Henan Provincial Drug Administration, indicating that its production facilities and management systems meet the requirements of drug production quality management standards [1]. Group 1 - The subsidiary, Xinxiang Pharmaceutical, successfully passed the GMP compliance inspection for the production lines related to the active pharmaceutical ingredients (APIs) Olaparib (an anti-tumor drug) and Cytidine Diphosphate Choline [1]. - The approval signifies a critical step for the company in ensuring the quality and compliance of its pharmaceutical production processes [1]. - This development may enhance the company's market position and potential for future growth in the pharmaceutical sector [1].
拓新药业(301089.SZ)子公司新乡制药收到药品GMP符合性检查告知书